Why the study?
Cerebrovascular events are serious complications of TAVR driven largely by acute emboli, leading to the development of cerebral embolic protection devices to reduce periprocedural ischemic events and silent lesions.
This review summarizes the rationale, device types, and clinical data for cerebral embolic protection devices used to reduce peri-procedural ischemic events during TAVR.
Answers are grounded in this paper and cite their sources.
Offers clinicians a synthesis of cerebral embolic protection options in TAVR; leaves open the need for definitive RCTs to guide routine use.
Transcatheter aortic valve replacement (TAVR) has become a first-line treatment for severe aortic stenosis with intermediate to high-risk population with its use increasingly expanding into younger and low-risk cohorts as well. Cerebrovascular events are one of the most serious consequential complications of TAVR, which increase morbidity and mortality. The most probable origin of such neurological events is embolic in nature and the majority occur in the acute phase after TAVR when embolic events are most frequent. Cerebral embolic protection devices have been designed to capture or deflect these emboli, reducing the risk of peri-procedural ischaemic events. They also carry the potential to diminish the burden of new silent ischemic lesions during TAVR. Our review explores different types of these device systems, their rationale, and the established clinical data.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: